--- title: "Niagen Bioscience sets up $50,000,000 share sales program" url: "https://aibio.space/news/niagen-bioscience-sets-up-50-000-000-share-sales-program/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-07-10" section: "Financings" tickers: "NASDAQ:NAGE" source: "https://www.sec.gov/Archives/edgar/data/1386570/000121390026077234/ea0297322-424b5_niagen.htm" summary: "Canaccord Genuity and Roth Capital Partners are the sales agents under a June 26, 2026 agreement, for a 3% commission. The supplement puts net tangible boo" --- By the aibio.space news desk. Sources - [Niagen Bioscience, Inc. 424B5 (2026-07-10)](https://www.sec.gov/Archives/edgar/data/1386570/000121390026077234/ea0297322-424b5_niagen.htm) [NAGE](https://aibio.space/companies/niagen-bioscience/) 2026-07-10 # Niagen Bioscience sets up $50,000,000 share sales program Tickers [NAGE](https://aibio.space/companies/niagen-bioscience/) Canaccord Genuity and Roth Capital Partners are the sales agents under a June 26, 2026 agreement, for a 3% commission. The supplement puts net tangible book value at $0.97 a share against a $3.37 reference price. ## Key facts - **Company**: Niagen Bioscience, Inc. (NASDAQ: NAGE) - **News type**: Financings - **Primary source**: [Niagen Bioscience, Inc. 424B5 (2026-07-10)](https://www.sec.gov/Archives/edgar/data/1386570/000121390026077234/ea0297322-424b5_niagen.htm) *A trading board being updated by hand. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* Niagen Bioscience, Inc. (Nasdaq: [NAGE](https://aibio.space/companies/niagen-bioscience/)) filed a prospectus supplement on July 10, 2026 for the sale of up to $50,000,000 of its common stock through an at-the-market program. The supplement sits under a sales agreement dated June 26, 2026 with Canaccord Genuity LLC and Roth Capital Partners, LLC, which may act as agents or principals. ## The terms Shares may be sold by any method that counts as an at-the-market offering under the Securities Act rules. The agents will use commercially reasonable efforts to sell the shares Niagen asks them to sell, and Niagen says it has discretion, subject to market demand, to vary the timing, prices and numbers of shares sold. The filing says there is no escrow, trust or similar arrangement for the money received. The agents receive 3% of the gross proceeds of each share sold. The supplement says the agents will be deemed underwriters under the Securities Act and that their pay will be treated as underwriting commissions or discounts. Niagen will also indemnify the agents for certain liabilities, including those under the Securities Act, and reimburse their expenses, including counsel fees, up to $75,000 at the start and up to $15,000 per quarter after that. The supplement says the total sold, the commissions and the proceeds cannot be determined now, because there is no minimum amount that must be raised. The shares trade on the Nasdaq Capital Market, and the last reported sale price on July 8, 2026 was $3.37. ## Who is named Canaccord Genuity LLC and Roth Capital Partners, LLC are the only sales agents named. The supplement says both have provided, and may in the future provide, investment banking and other financial services to the company, and that they have received or may receive customary fees for that work. Proskauer Rose LLP of Los Angeles has passed on the validity of the common stock for Niagen. Duane Morris LLP of New York represents the sales agents. Crowe LLP audited the 2025 financial statements incorporated by reference. The supplement names no placement agent, underwriter or bank beyond the two sales agents. ## Dilution on the filing's own figures The supplement puts Niagen's net tangible book value at approximately $76.8 million, or $0.97 per share, as of March 31, 2026. If the full $50 million were sold at an assumed price of $3.37 per share, net tangible book value would rise to about $125.1 million, or $1.32 per share, after commissions and expenses. That is an increase of $0.36 per share for existing holders and an immediate dilution of $2.05 per share for new investors. The table is based on 79,624,227 shares outstanding at March 31, 2026. It excludes 9,941,125 shares that could be issued on exercise of outstanding options, at a weighted-average exercise price of $3.80, and 1,603,071 shares underlying restricted stock units. The supplement warns that investors could face further dilution as those awards are exercised or vest. ## Use of the money The supplement says the net proceeds would go to working capital and general corporate purposes, including capital expenditures and general and administrative expenses. It says management has not designated any particular purpose and will have broad discretion over the money, and that the proceeds may not improve the company's financial condition or market value. ## The business and its recent results Niagen sells Tru Niagen, a consumer supplement, and Niagen Plus, which features pharmaceutical-grade injectable and intravenous products that FDA-registered 503B outsourcing facilities compound and distribute for use with a prescription. Its annual report for 2025, filed March 4, 2026, shows revenue of $129.4 million, against $99.6 million for 2024. Net income was $17.4 million, against $8.6 million, and cash provided by operations was $13.5 million, against $12.1 million. Research and development expense was $6.3 million, against $6.0 million. Year-end 2024 cash and cash equivalents were $44.5 million. ## What the filing leaves open The supplement gives no cash balance, so the $50 million program cannot be set against cash on hand from the filing itself. It sets no timetable for sales and no minimum amount, and it does not say how much of the $50 million the company expects to sell. Sales will follow the market price, so the dilution actually suffered depends on sales that have not yet happened. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story NAGE Niagen Bioscience, Inc. NASDAQ ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/niagen-bioscience-sets-up-50-000-000-share-sales-program/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Niagen Bioscience sets up $50,000,000 share sales program", 2026-07-10, https://aibio.space/news/niagen-bioscience-sets-up-50-000-000-share-sales-program/